The 10th International Forum of The Japanese Society of Gastroenterology

DAY1

Time & Date: 9:05~17:10, Thursday, April 15, 2021 Place: Room 5 (4F, Ohgi Room, Keio Plaza Hotel)

Main Theme: Acute-on-Chronic Liver Failure (ACLF): Difference among APASL, EASL, AASLD

and Japan

Opening Remarks $(9:05\sim9:10)$

Satoshi Motchida (Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan)

Acute-on-Chronic Liver Failure (ACLF), in Japan, Asia and Europe/the United States (9:10~11:40)

Moderators: Akio Ido (Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Japan)

Isao Sakaida (Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Japan)

IF1-1 ACLF-New Diagnostic & Therapeutic Tools
Shiy Kumar Sarin (Department of Hepatology, Insti

Shiv Kumar Sarin (Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), India)

IF1-2 ACLF in Japan, Asia, Europe and the United States

Rajiv Jalan (Liver Failure Group, Institute for Liver and Digestive Health, University College London, UK)

IF1-3 Clinical development of Advanced Medicinal Therapy for patients with ACLF

Etienne M Sokal (UCLouvain, Institute of Experimental and Clinical Research (IREC), Laboratory of Pediatric Hepatology and Cell

Therapy, Belgium/Cliniques Universitaires Saint-Luc, Pediatric Hepatology & Gastroenterology Unit, Belgium/

IF1-4 Recent status of ACLF in Japan

Nobuaki Nakayama (Department of Gastroenterology & Hepatology, Saitama Medical University, Japan)

Promethera Biosciences, Belgium)

ACLF, and young hepatologists from Japan, Europe and Asia

 $(14:40\sim17:10)$

Moderators: Shuji Terai (Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan)

Nobuaki Nakayama (Department of Gastroenterology & Hepatology, Saitama Medical University, Japan)

IF2-1 Management of acute on chronic liver failure in Asia [Pros&Cons] Vinod Arora (Department of Hepatology, ILBS, India)

IF2-2	Actual state of Medical Treatment for ACLF in Europe
[Pros&Cons]	Jane Suzanne Macnaughtan (Institute for Liver and Digestive Health,
IF2-3	University College London, UK) Nationwide Survey for Acute-on-Chronic Liver Failure in Japan
1Γ <i>2</i> -3	Nobuaki Nakayama (Department of Gastroenterology & Hepatology, Saitama
	Medical University, Japan)
IF2-4	Role of hepatitis A virus infection in acute-on-chronic liver failure
	Tatsuo Kanda (Division of Gastroenterology and Hepatology, Department of
	Medicine, Nihon University School of Medicine, Japan)
IF2-5	Increased endotoxin activity is associated with therisk of developing acute-on- chronic liver failure
	Hiroaki Takaya (Department of Gastroenterology, Nara Medical University,
	Japan)
IF2-6	Precipitant and prognosis in acute decompensation/acute-on-chronic liver
	failure: single center experience
	Hitomi Hoshi (Division of Gastroenterology and Hepatology, Department of
	Internal Medicine, Keio University School of Medicine, Japan)
IF2-7	Indication of liver transplantation in the treatment of newly categorized acute- on-chronic liver failure in Japan
	Kaori Kuramitsu (Department of Surgery, Division of Hepato-biliary and
	Pancreatic Surgery, Kobe University, Japan)
IF2 - 8	Indication of liver transplantation to the patients with severe alcoholic
	hepatitis: Efficacy and ethical issue
	Keisuke Kakisaka (Division of Hepatology, Department of Internal Medicine,
	Iwate Medical University, Japan)
IF2 - 9	Improvementof hepatocyte senescence for acute on chronic liver failure
	Yusuke Watanabe (Division of Preemptive Medicine for Digestive Disease and
	Healthy Active Life, School of Medicine, Niigata
	University, Japan)

Closing Remarks

Rajiv Jalan (Liver Failure Group, Institute for Liver and Digestive Health, University College London, UK)

Shiv Kumar Sarin (Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), India)